This approach could be an important consideration in the management of heavily pretreated patients with chemorefractory multiple myeloma, even at the stage of terminal illness with extramedullary ...

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

A novel combination for relapsed/refractory multiple myeloma ... Staging System III myeloma, six of eight with high-risk cytogenetics, and 11 of 18 with extramedullary disease.